Literature DB >> 23344477

Change in the estimated glomerular filtration rate over time and risk of all-cause mortality.

Tanvir C Turin1, Josef Coresh, Marcello Tonelli, Paul E Stevens, Paul E de Jong, Christopher K T Farmer, Kunihiro Matsushita, Brenda R Hemmelgarn.   

Abstract

Using a community-based cohort we studied the association between changes in the estimated glomerular filtration rate (eGFR) over time and the risk of all-cause mortality. We identified 529,312 adults who had at least three outpatient eGFR measurements over a 4-year period from a provincial laboratory repository in Alberta, Canada. Two indices of change in eGFR were evaluated: the absolute annual rate of change (in ml/min per 1.73 m(2) per year) and the annual percentage change (percent/year). The adjusted mortality risk associated with each category of change in eGFR was assessed, using stable eGFR (no change) as the reference. Over a median follow-up of 2.5 years there were 32,372 deaths. Compared to the reference participants, those with the greatest absolute annual decline less than or equal to 5 ml/min per 1.73 m(2) per year had significantly increased mortality (hazard ratio of 1.52) adjusted for covariates and kidney function at baseline (last eGFR measurement). Participants with the greatest increase in eGFR of 5 ml/min per 1.73 m(2) per year or more also had significantly increased mortality (adjusted hazard ratio of 2.20). A similar pattern was found when change in eGFR was quantified as an annual percentage change. Thus, both declining and increasing eGFR were independently associated with mortality and underscore the importance of identifying change in eGFR over time to improve mortality risk prediction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23344477     DOI: 10.1038/ki.2012.443

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  46 in total

1.  Past Decline Versus Current eGFR and Subsequent Mortality Risk.

Authors:  David M J Naimark; Morgan E Grams; Kunihiro Matsushita; Corri Black; Iefke Drion; Caroline S Fox; Lesley A Inker; Areef Ishani; Sun Ha Jee; Akihiko Kitamura; Janice P Lea; Joseph Nally; Carmen Alicia Peralta; Dietrich Rothenbacher; Seungho Ryu; Marcello Tonelli; Hiroshi Yatsuya; Josef Coresh; Ron T Gansevoort; David G Warnock; Mark Woodward; Paul E de Jong
Journal:  J Am Soc Nephrol       Date:  2015-12-11       Impact factor: 10.121

2.  Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression.

Authors:  Aron Chakera; Clare MacEwen; Shubha S Bellur; La-Or Chompuk; Daniel Lunn; Ian S D Roberts
Journal:  J Nephrol       Date:  2015-08-30       Impact factor: 3.902

3.  Rate of change in renal function and mortality in elderly treated hypertensive patients.

Authors:  Enayet K Chowdhury; Robyn G Langham; Zanfina Ademi; Alice Owen; Henry Krum; Lindon M H Wing; Mark R Nelson; Christopher M Reid
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-21       Impact factor: 8.237

4.  GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.

Authors:  Lesley A Inker; Hiddo J L Heerspink; Hocine Tighiouart; Andrew S Levey; Josef Coresh; Ron T Gansevoort; Andrew L Simon; Jian Ying; Gerald J Beck; Christoph Wanner; Jürgen Floege; Philip Kam-Tao Li; Vlado Perkovic; Edward F Vonesh; Tom Greene
Journal:  J Am Soc Nephrol       Date:  2019-07-10       Impact factor: 10.121

5.  Evidence-Based Decision Making 6: Administrative Databases as Secondary Data Source for Epidemiologic and Health Service Research.

Authors:  Tanvir Turin Chowdhury; Brenda R Hemmelgarn
Journal:  Methods Mol Biol       Date:  2021

6.  Change in Multiple Filtration Markers and Subsequent Risk of Cardiovascular Disease and Mortality.

Authors:  Casey M Rebholz; Morgan E Grams; Kunihiro Matsushita; Lesley A Inker; Meredith C Foster; Andrew S Levey; Elizabeth Selvin; Josef Coresh
Journal:  Clin J Am Soc Nephrol       Date:  2015-03-30       Impact factor: 8.237

7.  Past Decline Versus Current eGFR and Subsequent ESRD Risk.

Authors:  Csaba P Kovesdy; Josef Coresh; Shoshana H Ballew; Mark Woodward; Adeera Levin; David M J Naimark; Joseph Nally; Dietrich Rothenbacher; Benedicte Stengel; Kunitoshi Iseki; Kunihiro Matsushita; Andrew S Levey
Journal:  J Am Soc Nephrol       Date:  2015-12-11       Impact factor: 10.121

8.  The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive Medications.

Authors:  Joshua I Barzilay; Barry R Davis; Sara L Pressel; Alokananda Ghosh; Mahboob Rahman; Paula T Einhorn; William C Cushman; Paul K Whelton; Jackson T Wright
Journal:  Am J Hypertens       Date:  2018-04-13       Impact factor: 2.689

Review 9.  Renal function trajectory over time and adverse clinical outcomes.

Authors:  Badrul Munir Sohel; Nahid Rumana; Masaki Ohsawa; Tanvir Chowdhury Turin; Martina Ann Kelly; Mohammad Al Mamun
Journal:  Clin Exp Nephrol       Date:  2016-01-04       Impact factor: 2.801

10.  Long-term outcomes of renal function after radioactive iodine therapy for thyroid cancer according to preparation method: thyroid hormone withdrawal vs. recombinant human thyrotropin.

Authors:  Yoon Young Cho; Soo Kyoung Kim; Jung Hwa Jung; Jong Ryeal Hahm; Tae Hyuk Kim; Jae Hoon Chung; Sun Wook Kim
Journal:  Endocrine       Date:  2018-11-23       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.